Antony Blanc
Corporate Officer/Principal bij CUREVAC N.V.
Vermogen: 7 781 $ op 31-03-2024
Actieve functies van Antony Blanc
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CUREVAC N.V. | Corporate Officer/Principal | 04-12-2020 | - |
Loopbaan van Antony Blanc
Eerdere bekende functies van Antony Blanc
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Mckinsey & Co., Inc. (Germany) | Corporate Officer/Principal | 01-01-2009 | 01-01-2017 |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Corporate Officer/Principal | 01-01-2000 | 01-01-2009 |
SYNGENTA | Corporate Officer/Principal | 01-01-2000 | 01-01-2009 |
Opleiding van Antony Blanc
McGill University | Doctorate Degree |
Statistieken
Internationaal
Zwitserland | 3 |
Duitsland | 3 |
Canada | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Process Industries | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CUREVAC N.V. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Syngenta AG
Syngenta AG Chemicals: AgriculturalProcess Industries Syngenta AG specializes in crop protection and seeds production. Its products include selective and non-selective herbicides, fungicides, insecticides, as well as field crop and vegetable seeds. The company was founded on November 12, 1999 and is headquartered in Basel, Switzerland. | Process Industries |
Mckinsey & Co., Inc. (Germany) |
- Beurs
- Insiders
- Antony Blanc
- Ervaring